Abstract | BACKGROUND: The study 20050181 demonstrated significant improvements in progression-free survival (PFS), objective response, and a nonsignificant trend toward increased overall survival (OS) with panitumumab-FOLFIRI versus FOLFIRI alone for second-line wild-type (WT) KRAS metastatic colorectal cancer (mCRC). Updated long-term data from a prespecified descriptive analysis are reported. PATIENTS AND METHODS: Patients receiving one prior mCRC treatment were randomly assigned (1:1) to panitumumab (6.0 mg/kg)-FOLFIRI versus FOLFIRI every 2 weeks. Co-primary end points (PFS and OS) were prospectively analyzed by tumor KRAS status. RESULTS: One thousand one hundred and eighty-six patients were randomly assigned. In patients with WT KRAS tumors, panitumumab-FOLFIRI significantly improved PFS versus FOLFIRI [median 6.7 versus 4.9 months; hazard ratio (HR) 0.82 [95% confidence interval (CI) 0.69, 0.97]; P = 0.023]. A trend toward longer OS was observed (median 14.5 versus 12.5 months; HR 0.92 [95% CI 0.78, 1.10]; P = 0.37). Response rates improved from 10% to 36% (P < 0.0001). From post hoc analyses in patients receiving prior oxaliplatin- bevacizumab, panitumumab-FOLFIRI improved PFS (median 6.4 versus 3.7 months; HR 0.58 [95% CI 0.37, 0.90]; P = 0.014). PFS and OS appeared longer for worst-grade skin toxicity of 2-4, versus 0-1 or FOLFIRI. Safety results were as previously reported and consistent with the known toxicities with anti- epidermal growth factor receptor therapy. CONCLUSIONS: These data confirm the primary efficacy and safety findings of this trial and support panitumumab-FOLFIRI as a second-line treatment of WT KRAS mCRC.
|
Authors | M Peeters, T J Price, A Cervantes, A F Sobrero, M Ducreux, Y Hotko, T André, E Chan, F Lordick, C J A Punt, A H Strickland, G Wilson, T E Ciuleanu, L Roman, E Van Cutsem, Y Tian, R Sidhu |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology
(Ann Oncol)
Vol. 25
Issue 1
Pg. 107-16
(Jan 2014)
ISSN: 1569-8041 [Electronic] England |
PMID | 24356622
(Publication Type: Clinical Trial, Phase III, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal
- Panitumumab
- Leucovorin
- Fluorouracil
- Camptothecin
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Camptothecin
(adverse effects, analogs & derivatives, therapeutic use)
- Colorectal Neoplasms
(drug therapy, mortality, pathology)
- Disease-Free Survival
- Female
- Fluorouracil
(adverse effects, therapeutic use)
- Humans
- Kaplan-Meier Estimate
- Leucovorin
(adverse effects, therapeutic use)
- Liver Neoplasms
(drug therapy, mortality, secondary)
- Male
- Middle Aged
- Panitumumab
- Quality of Life
- Skin Diseases
(chemically induced)
- Treatment Outcome
|